Key Publications
LAG-3 technology and Immutep's soluble LAG-3 products are cited in the following publications:
1- Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevée, C., Viegas-Pequignot, E. and Hercend, T., LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 1990. 171: 1393-1405.
2- Baixeras, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F. and Piatier-Tonneau, D., Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J. Exp. Med. 1992. 176: 327-337.
3- Huard, B., Gaulard, P., Faure, F., Hercend, T. and Triebel, F., Cellular expression and tissue distribution of the human LAG-3-encoded protein, a MHC class II ligand. Immunogenetics 1994. 39: 213-217.
4- Huard, B., Prigent, P., Tournier, M., Bruniquel, D. and Triebel, F., CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur. J. Immunol. 1995. 25: 2718-2721.
5- Annunziato, F., Manetti, R., Tomasevic, L., Guidizi, M.-G., Biagiotti, R., Gianno, V., Germano, P., Mavilia, C., Maggi, E. and Romagnani, S., Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. FASEB J. 1996. 10: 769-776.
6- Huard, B., Prigent, P., Pages, F., Bruniquel, D. and Triebel, F., T cell MHC class II molecules downregulate CD4+ T cell clone response following LAG-3 binding. Eur. J. Immunol. 1996. 26: 1180-1186.
7- Mastrangeli, R., Micangeli, E. and Donini, S., Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (GENE-CAPTURE PCR). Anal. Biochem. 1996. 241: 93-102.
8- Miyazaki, T., Dierich, A., Benoist, C. and Mathis, D., Independent modes of natural killing distinguished in mice lacking LAG-3. Science 1996. 272: 405-408.
9- Miyazaki, T., Dierich, A., Benoist, C. and Mathis, D., LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. Int. Immunol. 1996. 8: 725-729.
10- Annunziato, F., Manetti, R., Cosmi, L., Galli, G., Heusser, C. H., Romagnani, S. and Maggi, E., Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur. J. Immunol. 1997. 27: 2239-2244.
11- Bruniquel, D., Borie, N. and Triebel, F., Genomic organization of the human LAG-3/CD4 locus. Immunogenetics 1997. 47: 96-98.
12- Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., El-Tayar, N., Maigret, B., Dreano, M. and Triebel, F., Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl. Acad. Sci. USA 1997. 94: 5744-5749.
13- Bruniquel, D., Borie, N., Hannier, S. and Triebel, F., Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics 1998. 48: 116-124.
14- Hannier, S., Tournier, M., Bismuth, G. and Triebel, F.,CD3/TCR complex-associated LAG-3 molecules inhibit CD3/TCR signaling. J. Immunol. 1998. 161: 4058-4065.
15- Huard, B., Tournier, M. and Triebel, F., LAG-3 does not define a specific mode of natural killing in human. Immunol. Lett. 1998. 61: 109-112.
16- Subramanyam, M., Wands, G., Nabioullin, R. and Tepper, M. A., Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses. Int. Immunol. 1998. 10: 679-689.
17- Scala, E., Carbonari, M., Del Porto, P., Cibati, M., Tedesco, T., Mazzone, A. M., Paganelli, R. and Fiorilli M., Lymphocyte Activation Gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations. J. Immunol.1998. 10: 489-493.
18- Avice, M. N., Sarfati, M., Triebel, F., Delespesse, G. and Demeure, C. E., Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J. Immunol. 1999. 162: 2748-2753.
19- Hannier, S. and Triebel, F.,
20- Prigent, P., Mir, S. E., Dreano, M. and Triebel, F., LAG-3 induces tumor regression and antitumor immune responses in vivo. Eur. J. Immunol. 1999. 29: 3867-3876.
21- El mir, S. and Triebel, F., A soluble LAG-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J. Immunol. 2000. 164: 5583-5589.
22- Demeure, C., Wolfers, J., Martin-Garcia, N., Gaulard, P. and Triebel, F., T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur. J. Cancer 2001. 73: 1709-1718.
23- Iouzalen, N., Andreae, S., Hannier S, Triebel F., LAP, a lymphocyte activation gene-3 (LAG-3)-LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. Eur. J. Immunol. 2001. 31: 2885-2891.
24- Andreae, S., Piras, F., Burdin, N. and Triebel, F., Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J. Immunol. 2002. 168: 3874-3880.
25- Workman, C. J., Rice, D. S., Dugger, K. J., Kurschner C. and Vignali D. A., Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur. J. Immunol. 2002. 32: 2255-2263.
26- Triebel F. 2002. LAG-3 (CD223), a molecule lagging behind : time for a boost ?Leucocyte Typing VII. Ed. D. Mason, Oxford University Press. p485.
27- Workman, C. J., Dugger, K. J. and Vignali D. A., Molecular analysis of the negative regulatory function of Lymphocyte Activation Gene-3. J. Immunol. 2002. 169: 5392-5395.
28- Workman, C. J. and Vignali D. A., The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur. J. Immunol. 2003. 33: 970-979.
29- Buisson, S. and Triebel, F., MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells. Vaccine 2003. 21: 862-868.
30- Cappello P., Triebel, F., Iezzi, M., Caorsi, C., Quaglino E., Lollini, P-L., Amici, A., Di Carlo, E., Musiani, P., Giovarelli, M. and Forni, G., LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res.2003. 63: 2518-2525.
31- Andreae, S., Buisson, S. and Triebel, F., MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 2003. 102: 2130-2137.
32- Triebel, F., LAG-3: a regulator of T-cell and DC responses ans its use in therapeutic vaccination. Trends in Immunol. 2003. 24: 619-622.
33- Workman, C. J., Cauley, L. S., Kim, I. J., Blackman M. A., Woodland, D. L. and Vignali D. A. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J.Immunol.2004. 172: 5450-5455.
34- Huang, C-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., Powell, J. D., Pardoll, D. M., Drake, C. G and Vignali, D. A. Role of LAG-3 in regulatory T cells. Immunity 2004. 21: 503-513.
35- Li, N. L., Workman, C. J., Martin S. M. and Vignali D., A. Biochemical analysis of the regulatory T cell protein Lymphocyte Activation gene-3 (LAG-3; CD223). J.Immunol. 2004. 73: 6806-6812.
36- Di Carlo, E., Capello, P., Sorrentino, C., D'Antuono, T., Pellicciotta, A., Giovarelli, M., Forni, G., Musiani, P. and Triebel F. Immunological mechanisms elicited at the tumour site by Lymphocyte Activation Gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J. Pathol. 2005. 205: 82-91.
37- Buisson, S. and Triebel F., LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology 2005. 114:369-374.
38- Macon-Lemaitre, L., and Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005. 115:170-178.
39- Ausiello, C. M., R. Palazzo, F. Spensieri, F. Urbani, M. Massari, F. Triebel, M. Benagiano, M. M. D'Elios, G. Del Prete, and Cassone A. Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine. Int. J. Immunopathol. Pharmacol. 2006. 19:97-104.
40- Triebel, F., K. Hacene, and Pichon M. F. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett. 2006. 235:147-153.
41- Casati, C., C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and Castelli C. Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res. 2006. 66:4450-4460.
42- Fougeray, S., C. Brignone, and Triebel F; A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321. Vaccine 2006. 24:5426-5433.
43- Bayry J.,Triebel F., Kaveri S. V. and Tough D. F. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J. Immunol. 2007. 178:4184-4193.
44- Brignone C., Grygar C. Marcu M., Perrin G. and Triebel F. IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J. Immune Based Ther. Vaccines. 2007. 5:5.
45- Brignone C., Grygar C. Marcu M., Perrin G. and Triebel F. IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: A single-blind phase I study. Vaccine. 2007. 25:4641-4650.
46- Brignone C., Grygar C. Marcu M., Perrin G. and Triebel F. A soluble form of LAG-3 (CD223) induces activation of a large range of human effector cytotoxic cells. J. Immunol. 2007. 15:179:4202-4211.
47- Grosso J.F., Kelleher C. C. et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 2007. 117:3383-3392.
48- Haudebourg T., Dugast A-S., Coulon F., Usal C., Triebel F. and Vanhove B. Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation. 2007. 84:1500-1506.
49- Casati C., Camisaschi C., Novellino L., Mazzocchi A., Triebel F., Rivoltini L., Parmiani G. and Castelli C. Human Lymphocyte Activation Gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation. J. Immunol. 2008. 180:3782-3788.
50- Li B., VanRoey M., Triebel F. and Jooss K. Lymphocyte Activation Gene-3 fusion protein increases the potency of a Granulocyte Colony-Stimulating Factor-secreting tumor cell immunotherapy. Clin. Cancer Res. 2008. 14:3545-3554.
